Compare Novo Nordisk A/S (NVO) vs Procter & Gamble Co (PG) Price & Performance

Novo Nordisk A/STrade

Procter & Gamble CoTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Procter & Gamble Co — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Procter & Gamble Co trades at $148.12 (market cap $347.26B). The key difference: Procter & Gamble Co is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.

	NVO	PG
Market Cap	$220.53B	$347.26B
Sector	Health	Consumer Staples
52-Week High	$71.70	$167.18
52-Week Low	$35.29	$138.10
Enterprise Value	$239.49B	$372.74B
Dividend Yield	3.63%	2.92%
Volume	—	6,423,436

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

No Aura AI signal available yet.

Procter & Gamble Co

Procter & Gamble (PG) trades at $148.12, down 1.23% on the day, with a bullish technical outlook supported by moving averages and key resistance at $150. The company shows steady revenue growth, with 2025 revenue at $84.28 billion and net income of $15.97 billion, alongside consistent quarterly earnings beats. Recent news highlights PG's dividend reliability and strategic partnerships, such as the WNBA deal announced on April 7, 2026.

PG offers a stable investment with a strong dividend history and moderate growth, but faces risks from premium valuations and economic sensitivity. Analyst consensus is bullish with a $161.71 price target, though near-term upside may be limited by high P/E and P/S ratios relative to peers.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 9 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 13 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

DIVO ETF up 6.6% YTD but faces pressure from high Treasury yields and low volatility.24/7 Wall Street · 4 days agoNeutral Vanguard High Dividend Yield ETF offers durable income with strong dividend coverage and steady returns.24/7 Wall Street · 4 days agoBullish SPYI ETF yields 12% but faces pressure as volatility drops and Treasury yields rise.24/7 Wall Street · 4 days agoNeutral View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Procter & Gamble Co

The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.